Early Australian experience with the CGRP inhibitor erenumab (Aimovig) shows it is an effective and well-tolerated migraine preventative therapy in real world usage. A review of the non-PBS-listed drug’s use in three Australian migraine centres via a product familiarisation program or a $800/month paid access scheme found that it provided consistent responses at three and ...
Erenumab efficacy reported for Australian migraine patients
By Michael Woodhead
6 Oct 2020